Manuel Baca

age ~59

from Lexington, MA

Get Report

Connected to:

Manuel Baca Phones & Addresses

12 Coolidge Ave, Lexington, MA 02420
Gaithersburg, MD
Foster City, CA
La Jolla, CA
Woodbury, NY
San Francisco, CA

Vehicle Records

Manuel Baca
view source
Address:

481 Phelps St, Gaithersburg, MD 20878
VIN:

WAUDF78E47A125769
Make:

AUDI
Model:

A4
Year:

2007

Us Patents

Anti-Vegf Antibodies
view source
US Patent:

7060269, Jun 13, 2006
Filed:

Nov 27, 2000
Appl. No.:

09/723752
Inventors:

Manuel Baca - Foster City CA, US
James A. Wells - Burlingame CA, US
Leonard G. Presta - San Francisco CA, US
Henry B. Lowman - El Granada CA, US
Yvonne Man-yee Chen - San Mateo CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

A61K 39/395
US Classification:

4241331, 4241561, 5303873, 53038885
Abstract:

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.

Anti-Vegf Antibodies
view source
US Patent:

7297334, Nov 20, 2007
Filed:

Oct 26, 2004
Appl. No.:

10/974591
Inventors:

Manuel Baca - Foster City CA, US
James A. Wells - Burlingame CA, US
Leonard G. Presta - San Francisco CA, US
Henry B. Lowman - El Granada CA, US
Yvonne Man-yee Chen - San Mateo CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

A61K 39/395
US Classification:

4241301, 4353201, 5303873, 53038885, 536 2353
Abstract:

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.

High Affinity Antibody Antagonists Of Interleukin-13 Receptor Alpha 1
view source
US Patent:

7754213, Jul 13, 2010
Filed:

Oct 19, 2007
Appl. No.:

11/875017
Inventors:

Andrew Donald Nash - Kew, AU
Manuel Baca - Gaithersburg MD, US
Louis Jerry Fabri - Diamond Creek, AU
Dennis Zaller - Scotch Plains NJ, US
William R. Strohl - Bridgewater NJ, US
Zhiqiang An - Ambler PA, US
Assignee:

Merck & Co., Inc. - Rahway NJ
CSL Limited - Parkville, Victoria
International Classification:

A61K 39/395
US Classification:

4241421, 4241431, 4241541, 53038815, 53038822, 53038875
Abstract:

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

Methods Of Treating Inflammatory Airway Conditions By Inhibition Of Il-11 Activity
view source
US Patent:

8182814, May 22, 2012
Filed:

Oct 23, 2008
Appl. No.:

12/256883
Inventors:

Manuel Baca - Gaithersburg MD, US
Andrew Donald Nash - Kew, AU
Jack A. Elias - Woodbridge CT, US
Assignee:

CSL Limited - Parkville, Victoria
Yale University - New Haven CT
International Classification:

A61K 38/20
C07K 14/715
C07K 14/54
C07K 16/28
C07K 16/24
US Classification:

4241431, 4241331, 4241391, 4241411, 4241451, 530351, 5303873, 53038822, 53038823
Abstract:

The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.

Il-11 Muteins
view source
US Patent:

8540977, Sep 24, 2013
Filed:

Jul 25, 2011
Appl. No.:

13/189850
Inventors:

Manuel Baca - Gaithersburg MD, US
Assignee:

CSL Limited - Parkville, Victoria
International Classification:

C07K 14/54
A61K 38/20
US Classification:

424 852, 424 851, 514 212, 530402
Abstract:

The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.

High Affinity Antibody Antagonists Of Interleukin-13 Receptor Alpha 1
view source
US Patent:

8568722, Oct 29, 2013
Filed:

May 6, 2010
Appl. No.:

12/774966
Inventors:

Andrew Donald Nash - Kew, AU
Manuel Baca - Gaithersburg MD, US
Louis Jerry Fabri - Diamond Creek, AU
Dennis Zaller - Scotch Plains NJ, US
William R. Strohl - Bridgewater NJ, US
Zhiqiang An - Ambler PA, US
Assignee:

CSL Limited - Parkville, Victoria
International Classification:

A61K 39/395
US Classification:

4241441
Abstract:

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

Anti-Il-13Rα1 Antibodies And Their Uses Thereof
view source
US Patent:

8613925, Dec 24, 2013
Filed:

Oct 19, 2007
Appl. No.:

12/445753
Inventors:

Andrew Donald Nash - Kew, AU
Manuel Baca - Gaithersburg MD, US
Louis Jerry Fabri - Diamond Creek, AU
Dennis Zaller - Scotch Plains NJ, US
William R. Strohl - Bridgewater NJ, US
Zhiqiang An - Ambler PA, US
Assignee:

CSL Limited - Parkville, Victoria
International Classification:

A61K 39/395
US Classification:

4241441
Abstract:

Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rα1-mediated activities are also disclosed.

Protein Scaffolds
view source
US Patent:

8633297, Jan 21, 2014
Filed:

Oct 31, 2008
Appl. No.:

12/739149
Inventors:

Herren Wu - Boyds MD, US
Manuel Baca - Gaithersburg MD, US
Jeffrey Swers - Rockville MD, US
Benoy Chacko - Gaithersburg MD, US
Assignee:

MedImmune, LLC - Gaithersburg MD
International Classification:

C07K 14/00
A61K 38/00
US Classification:

530300, 514 11
Abstract:

The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.

Resumes

Senior Director, Biologics Discovery

view source

Location:

Washington, DC

Industry:

Biotechnology

Work:

Gilead Sciences
Senior Director, Biologics Discovery
Juno Therapeutics, Inc. Aug 2016 - May 2017
Head of Cell and Protein Science
Medimmune Jan 2007 - Aug 2016
Fellow 2011-2016; Principal Scientist 2007-2011
Zenyth Therapeutics/Amrad Corp Jan 2004 - Jan 2007
Head of Antibody Technology
Walter and Eliza Hall Institute of Medical Research 1997 - 2003
Research Fellow, Lab Head

Education:

Scripps Research 1994
Scripps Research 1991 - 1994
Doctorates, Doctor of Philosophy, Molecular Biology, Biochemistry Unsw 1989
Bachelors, Bachelor of Science University of Sydney 1984 - 1988
Bachelors, Bachelor of Science, Chemistry

Skills:

Protein Chemistry
Antibodies
Drug Development
Protein Engineering
Life Sciences
Monoclonal Antibodies
Biotechnology
Biologics
Drug Discovery
Cancer
Phage Display
Molecular Biology
Cell Signaling
Protein Purification
Biochemistry
Assay Development
Biopharmaceuticals
Immunology
Chemistry
Protein Expression
Purification
Peptide Chemistry
Analytical Biochemistry
Technology Transfer

Languages:

English
Spanish

Blueball Buster

view source

Work:

Blueball
Blueball Buster

Manuel Baca

view source

President

view source

Work:

President

Manuel Baca

view source

Manuel Baca

view source

Manuel Baca

view source

Location:

United States

Name / Title

Company / Classification

Phones & Addresses

Manuel Baca
Owner, Chairman, Chief Executive Officer

Fenix Radio Dispatch
Local Passenger Transportation

586 Seneca Ave, Flushing, NY 11385
7188212121

Myspace

manuel baca

view source

Locality:

midland, Texas

Gender:

Male

Birthday:

1944

Manuel Baca

view source

Locality:

drugG toWn!, Mexico

Gender:

Male

Birthday:

1951

Manuel Baca

view source

Locality:

Corpus Christi, Texas

Gender:

Male

Birthday:

1939

Manuel Baca

view source

Locality:

ALBUQUERQUE, New Mexico

Gender:

Male

Birthday:

1950

Manuel Baca

view source

Locality:

Bernalillo, New Mexico

Gender:

Male

Birthday:

1943

MaNuel BaCa

view source

Locality:

209, stockton

Gender:

Male

Birthday:

1952

Manuel Baca

view source

Gender:

Male

Birthday:

1953

Plaxo

Manuel J. Baca

view source

News

High cost of first-year community college dropouts

view source

"We want to impose a 100-unit limit so that if students don't complete their work, they'll have to pay full cost, around $200 a unit," said Manuel Baca, a task force member who serves on the Community College Board of Governors.
Date: Oct 20, 2011
Category: U.S.
Source: Google